- Home
- MCRB vs SVII Comparison
MCRB vs SVII Comparison
Compare MCRB & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- SVII
- Stock Information
- Founded
- MCRB 2010
- SVII 2021
- Country
- MCRB United States
- SVII United States
- Employees
- MCRB N/A
- SVII N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- MCRB Health Care
- SVII Finance
- Exchange
- MCRB Nasdaq
- SVII Nasdaq
- Market Cap
- MCRB 131.0M
- SVII 111.1M
- IPO Year
- MCRB 2015
- SVII 2022
- Fundamental
- Price
- MCRB $0.73
- SVII $11.28
- Analyst Decision
- MCRB Buy
- SVII
- Analyst Count
- MCRB 4
- SVII 0
- Target Price
- MCRB $5.63
- SVII N/A
- AVG Volume (30 Days)
- MCRB 2.0M
- SVII 7.2K
- Earning Date
- MCRB 03-04-2025
- SVII 01-01-0001
- Dividend Yield
- MCRB N/A
- SVII N/A
- EPS Growth
- MCRB N/A
- SVII 13.16
- EPS
- MCRB N/A
- SVII 0.36
- Revenue
- MCRB $126,325,000.00
- SVII N/A
- Revenue This Year
- MCRB N/A
- SVII N/A
- Revenue Next Year
- MCRB N/A
- SVII N/A
- P/E Ratio
- MCRB N/A
- SVII $31.25
- Revenue Growth
- MCRB 12856.41
- SVII N/A
- 52 Week Low
- MCRB $0.54
- SVII $10.87
- 52 Week High
- MCRB $1.53
- SVII $11.70
- Technical
- Relative Strength Index (RSI)
- MCRB 37.88
- SVII 63.22
- Support Level
- MCRB $0.71
- SVII $11.20
- Resistance Level
- MCRB $0.91
- SVII $11.24
- Average True Range (ATR)
- MCRB 0.06
- SVII 0.00
- MACD
- MCRB -0.02
- SVII 0.00
- Stochastic Oscillator
- MCRB 8.37
- SVII 100.00
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.